0001493152-21-031802.txt : 20211217 0001493152-21-031802.hdr.sgml : 20211217 20211217073922 ACCESSION NUMBER: 0001493152-21-031802 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 13 CONFORMED PERIOD OF REPORT: 20211217 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20211217 DATE AS OF CHANGE: 20211217 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Sonnet BioTherapeutics Holdings, Inc. CENTRAL INDEX KEY: 0001106838 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 522102141 STATE OF INCORPORATION: DE FISCAL YEAR END: 0930 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-35570 FILM NUMBER: 211499513 BUSINESS ADDRESS: STREET 1: 100 OVERLOOK CENTER STREET 2: SUITE 102 CITY: PRINCETON STATE: NJ ZIP: 08540 BUSINESS PHONE: 609-375-2227 MAIL ADDRESS: STREET 1: 100 OVERLOOK CENTER STREET 2: SUITE 102 CITY: PRINCETON STATE: NJ ZIP: 08540 FORMER COMPANY: FORMER CONFORMED NAME: Chanticleer Holdings, Inc. DATE OF NAME CHANGE: 20050510 FORMER COMPANY: FORMER CONFORMED NAME: TULVINE SYSTEMS INC DATE OF NAME CHANGE: 20000214 8-K 1 form8-k.htm
0001106838 false 0001106838 2021-12-17 2021-12-17 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): December 17, 2021

 

SONNET BIOTHERAPEUTICS HOLDINGS, INC.

(Exact name of registrant as specified in its charter)

 

Delaware   001-35570   20-2932652

(State or other jurisdiction

of incorporation)

  

(Commission

File Number)

  

(IRS Employer

Identification No.)

 

100 Overlook Center, Suite 102

Princeton, New Jersey 08540

(Address of principal executive offices)

 

Registrant’s telephone number, including area code: (609) 375-2227

 

N/A

(Former name or former address, if changed since last report.)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
   
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
   
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
   
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol(s)   Name of each exchange on which registered
Common Stock, $0.0001 Par Value   SONN   The Nasdaq Stock Market LLC

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company ☐

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

 

 

 

Item 2.02. Results of Operations and Financial Condition.

 

On December 17, 2021, Sonnet BioTherapeutics Holdings, Inc. (the “Registrant”) issued a press release regarding financial results for the fiscal year ended September 30, 2021. A copy of the press release is furnished as Exhibit 99.1 hereto and is incorporated by reference herein.

 

Forward-Looking Statements

 

This report, including Exhibit 99.1 furnished herewith, contains forward-looking statements within the meaning of the federal securities laws. Forward-looking statements typically are identified by use of terms such as “may,” “will,” “should,” “plan,” “expect,” “anticipate,” “estimate” and similar words, and the opposites of such words, although some forward-looking statements are expressed differently. Forward-looking statements involve known and unknown risks and uncertainties that exist in the Registrant’s operations and business environment, which may be beyond the Registrant’s control, and which may cause actual results, performance or achievements to be materially different from future results, performance or achievements expressed or implied by such forward-looking statements. All statements other than statements of historical fact are statements that could be forward- looking statements. For example, forward-looking statements include, without limitation: statements regarding prospects for additional customers; market forecasts; projections of earnings, revenues, synergies, accretion or other financial information; and plans, strategies and objectives of management for future operations. The risks and uncertainties referred to above include, but are not limited to, risks detailed from time to time in the Registrant’s filings with the Securities and Exchange Commission, including its Annual Report on Form 10-K for the year ended September 30, 2021. These risks could cause actual results to differ materially from those expressed in any forward- looking statements made by, or on behalf of, the Registrant. Forward-looking statements represent the judgment of management of the Registrant regarding future events. Although the Registrant believes that the expectations reflected in such forward-looking statements are reasonable at the time that they are made, the Registrant can give no assurance that such expectations will prove to be correct. Unless otherwise required by applicable law, the Registrant assumes no obligation to update any forward-looking statements, and expressly disclaims any obligation to do so, whether as a result of new information, future events or otherwise.

 

Item 9.01. Financial Statements and Exhibits.

 

(d) Exhibits.

 

Exhibit No.   Exhibit
     
99.1   Press Release, dated December 17, 2021
104   Cover Page Interactive Data File (embedded within the Inline XBRL document)

 

 

 

 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  Sonnet BioTherapeutics Holdings, Inc.
  a Delaware corporation
  (Registrant)
   
Date: December 17, 2021 By: /s/ Pankaj Mohan, Ph.D.
  Name: Pankaj Mohan, Ph.D.
  Title: Chief Executive Officer

 

 

 

 EX-99.1 2 ex99-1.htm

 

Exhibit 99.1

 

Sonnet BioTherapeutics Provides Fiscal Year 2021 Business and Financial Update

 

PRINCETON, NJ / ACCESSWIRE / December 17, 2021 / Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN) (“Sonnet” or the “Company”), a biopharmaceutical company developing innovative targeted biologic drugs, announced today its financial results for the fiscal year ended September 30th, 2021 and provided a business update.

 

Pankaj Mohan, Ph.D., Founder and CEO commented, “This year has been incredibly exciting for Sonnet. We identified a new bispecific candidate, SON-1410, and were granted patent-protection for our FHAB technology. Additionally, we generated compelling new data to progress our therapeutic pipeline, including successful preclinical studies for SON-1010 and SON-080, which set the stage for future clinical studies. We believe this positions us well for continued growth and advancement of our pipeline in 2022.”

 

Fiscal Year 2021 and Recent Corporate Updates

 

Financings Completed: On August 24th, Sonnet successfully completed its follow-on offering of 35,294,117 shares of common stock and investor warrants for total net proceeds of approximately $27.6 million.

 

In June 2021, Sonnet completed the final issuance of shares of its common stock under the At-the-Market Sales Agreement, pursuant to which the Company executed issuances of an aggregate of 7,454,238 shares for total net proceeds of $15.2 million.

 

Issuance of U.S. Patent for Platform Technology: On June 8th, Sonnet announced the USTPO issued U.S. Patent No. 11,028,166 entitled, “Albumin Domain Fusion Proteins”. The patent covers Sonnet’s Fully Human Albumin Binding (FHAB) technology and includes therapeutic fusion proteins that utilize FHAB for tumor targeting and retention and provide extended pharmacokinetics (PK). The patent carries a term effective until March 2039.

 

Completed Licensing Agreement with New Life Therapeutics: On May 3rd, Sonnet announced a definitive agreement with New Life Therapeutics of Singapore for the license of low-dose Interleukin 6, or IL-6, for the treatment of Diabetic Peripheral Neuropathy (DPN). The licensed territory includes the ASEAN countries of Singapore, Malaysia, Indonesia, Thailand, The Philippines, Cambodia, Brunei, Vietnam, Myanmar and Lao PDR.

 

Appointment of Richard Kenney and Manuel DaFonseca: On March 22nd, Sonnet announced the appointment of Richard Kenney, M.D. as Chief Medical Officer and Manuel DaFonseca, as Head of Clinical Operations.

 

Sonnet is pleased to provide the following updates on its pipeline assets:

 

SON-1010 (IL12-FHAB): On February 1st, Sonnet announced that it had successfully completed a non-human primate (NHP), non-GLP repeat-dose toxicology study of SON-1010. The drug candidate was well tolerated at doses far exceeding levels expected in future human clinical trials, without producing detectable cytokine imbalances. SON-1010 demonstrated an enhanced pharmacokinetic (PK) profile as compared to recombinant IL-12. Analysis of interferon-γ levels, a key biomarker of antitumor activity, continued to suggest potent pharmacodynamic (PD) effects in the monkeys studied.

 

 

 

 

On May 10th, Sonnet announced the completion of a successful GLP repeat dose toxicology study of SON-1010 in NHPs. The No Observed Adverse Event Level (NOAEL) following repeated administration was more than 50 times the anticipated equivalent human clinical dose in NHPs with no evidence of cytokine release syndrome. PK analysis of serum samples confirmed an enhanced profile of IL12-FHAB over recombinant human IL-12, with a half-life around 40 hours in NHPs. A significant increase in interferon-γ, a key pleiotropic cytokine associated with anti-tumor mechanisms, was observed following dosing with IL12-FHAB.

 

An IND for SON-1010 has been submitted to the FDA and additional product stability data will be submitted in the first quarter of 2022. Subject to FDA approval, we expect to initiate a US clinical trial in oncology patients with solid tumors during the first half of 2022. We are also preparing to initiate an Australian clinical trial in healthy volunteers during the first half of 2022 to study the compound’s PK and PD, in preparation for potential combination studies.

 

SON-080 (low-dose IL-6): On January 25th, Sonnet announced that Sonnet CH, a wholly owned subsidiary of Sonnet headquartered in Switzerland, had successfully completed a multiple dose NHP study of SON-080. The toxicology study demonstrated a wide safety margin with no adverse effects observed in male or female cynomolgus monkeys at the doses tested. Sonnet intends to file for an ex-US Phase 1b/2a pilot-scale efficacy study with SON-080 in CIPN during the first half of 2022. Pursuant to the license agreement the Company entered with New Life Therapeutics Pte., Ltd of Singapore in May 2021, Sonnet and New Life will be jointly responsible for developing SON-080 in DPN with the objective of initiating an ex-US pilot efficacy study in the second half of 2022.

 

SON-1210 (IL12-FHAB-IL15): SON-1210, Sonnet’s first bispecific candidate, is undergoing cell line and process development activities. Early development materials were used in a mouse tumor model study, and additional biodistribution studies are planned. This work will inform the Company’s decision about dosing in a forthcoming NHP study, expected to be initiated in the first half of 2022. Scale up and cGMP manufacturing is scheduled to be completed in the first half of 2022, which will support the GLP NHP study, as well as First-In-Human (FIH) studies. Sonnet expects to initiate the regulatory authorization process for solid tumor indications in the second half of 2022.

 

SON-1410 (IL18-FHAB-IL12): On August 30th, Sonnet announced that it had selected a novel development candidate after completing comparative studies in a mouse melanoma model. The candidate represents Sonnet’s second bispecific compound integrating interleukin 12 (IL-12) with the company’s FHAB platform. The target indications for SON-1410 will be melanoma and renal cancers.

 

Fiscal Year Ended September 30, 2021 Financial Results

 

Jay Cross, CFO, elaborated on Sonnet’s 2021 fiscal year results, saying, “The Company has made important forward progress with our balance sheet this fiscal year, and we expect to continue to deliver on our stated objectives of advancing our therapeutic pipeline. We believe we are in a good position to maintain our positive momentum through 2022.”

 

  ● As of September 30, 2021, Sonnet had $27.6 million cash on hand, an increase from last quarter after a public offering in which the Company sold 33,193,485 shares of its common stock and pre-funded warrants to purchase 2,100,632 shares of common stock.
  ● The Company currently has outstanding 60,250,637 shares of common stock and warrants to purchase an aggregate of 51,789,522 shares of common stock, with a weighted average exercise price per share of $1.45. In the event all warrants were exercised for cash, the Company could receive up to $75.2 million of additional capital.

 

 
 

 

Research and development expenses were $16.6 million for the year ended September 30, 2021, compared to $9.9 million for the year ended September 30, 2020. The increase of $6.8 million was primarily due to the development of the cell lines for IL12-FHAB, IL12-FHAB-IL15 and SON-080, and an increase in payroll and share-based compensation expense, as we continue to expand our operations. General and administrative expenses were $8.9 million for the year ended September 30, 2021, compared to $7.5 million for the year ended September 30, 2020. The increase of $1.4 million was primarily due to an increase in payroll and share-based compensation expense and insurance expenses related to directors and officer’s insurance, as we continue to expand our operations to support our research and development efforts, partially offset by a $1.4 million decrease in professional fees and transaction related fees.

 

About Sonnet BioTherapeutics Holdings, Inc.

 

Founded in 2011, Sonnet BioTherapeutics is an oncology-focused biotechnology company with a proprietary platform for innovating biologic drugs of single or bispecific action. Known as FHAB (Fully Human Albumin Binding), the technology utilizes a fully human single chain antibody fragment (scFv) that binds to and “hitch-hikes” on human serum albumin (HSA) for transport to target tissues. FHAB is the foundation of a modular, plug-and-play construct for potentiating a range of large molecule therapeutic classes, including cytokines, peptides, antibodies and vaccines.

 

Forward-Looking Statements

 

This press release contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and Private Securities Litigation Reform Act, as amended, including those relating to the Company’s product development, clinical and regulatory timelines, market opportunity, competitive position, possible or assumed future results of operations, business strategies, potential growth opportunities and other statements that are predictive in nature. These forward-looking statements are based on current expectations, estimates, forecasts and projections about the industry and markets in which we operate and management’s current beliefs and assumptions.

 

These statements may be identified by the use of forward-looking expressions, including, but not limited to, “expect,” “anticipate,” “intend,” “plan,” “believe,” “estimate,” “potential, “predict,” “project,” “should,” “would” and similar expressions and the negatives of those terms. These statements relate to future events or our financial performance and involve known and unknown risks, uncertainties, and other factors which may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Such factors include those set forth in the Company’s filings with the Securities and Exchange Commission. Prospective investors are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date of this press release. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.

 

Sonnet Biotherapeutics Investor Contact

 

Michael Morabito
Solebury Trout
917-936-8430
mmorabito@soleburytrout.com

 

 
 

 

Sonnet BioTherapeutics Holdings, Inc.

Consolidated Balance Sheets

 

   September 30, 
   2021   2020 
Assets          
Current assets:          
Cash  $27,622,067   $7,349,903 
Prepaid expenses and other current assets   1,189,474    287,738 
Total current assets   28,811,541    7,637,641 
Property and equipment, net   59,056    67,889 
Operating lease right-of-use asset   123,213    205,919 
Other assets   —    82,959 
Total assets  $28,993,810   $7,994,408 
Liabilities and stockholders’ equity          
Current liabilities:          
Related-party notes  $748   $21,184 
Accounts payable   3,781,299    2,057,559 
Accrued expenses   2,310,410    2,063,678 
Operating lease liability   94,520    82,060 
Deferred income   516,374    500,000 
Total current liabilities   6,703,351    4,724,481 
Note payable   —    124,878 
Operating lease liability   30,612    125,132 
Total liabilities   6,733,963    4,974,491 
           
Commitments and contingencies (note 8)          
           
Stockholders’ equity:          
Preferred stock; $0.0001 par value: 5,000,000 shares authorized. No shares issued or outstanding   —    — 
Common stock; $0.0001 par value: 125,000,000 shares authorized; 60,250,637 and 14,724,105 issued and outstanding at September 30, 2021 and 2020, respectively   6,025    1,472 
Additional paid-in capital   83,943,040    39,723,702 
Accumulated deficit   (61,689,218)   (36,705,257)
Total stockholders’ equity   22,259,847    3,019,917 
Total liabilities and stockholders’ equity  $28,993,810   $7,994,408 

 

See 10-K filed today for notes to consolidated financial statements

 

 

 

 

Sonnet BioTherapeutics Holdings, Inc.

Consolidated Statements of Operations

 

   Years ended September 30, 
   2021   2020 
Collaboration revenue  $483,626   $— 
Operating expenses:          
Research and development   16,634,553    9,877,555 
Acquired in-process research and development   —    6,826,495 
General and administrative   8,936,509    7,533,722 
Total operating expenses   25,571,062    24,237,772 
Loss from operations   (25,087,436)   (24,237,772)
           
Interest income   15    20,677 
Foreign exchange loss   (22,041)   (48,020)
Other income   125,501    — 
Net loss   (24,983,961)   (24,265,115)
Deemed dividend arising from warrant amendment   —    (41,338,934)
Net loss attributable to common stockholders  $(24,983,961)  $(65,604,049)
Per share information:          
Net loss per share, basic and diluted  $(1.02)  $(6.96)
Weighted average shares outstanding, basic and diluted   24,547,290    9,420,484 

 

See 10-K filed today for notes to consolidated financial statements

 

SOURCE: Sonnet BioTherapeutics Holdings, Inc.

 

 

 

 EX-101.SCH 3 sonn-20211217.xsd XBRL SCHEMA FILE 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 4 sonn-20211217_lab.xml XBRL LABEL FILE Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 5 sonn-20211217_pre.xml XBRL PRESENTATION FILE XML 6 form8-k_htm.xml IDEA: XBRL DOCUMENT 0001106838 2021-12-17 2021-12-17 iso4217:USD shares iso4217:USD shares 0001106838 false 8-K 2021-12-17 SONNET BIOTHERAPEUTICS HOLDINGS, INC. DE 001-35570 20-2932652 100 Overlook Center Suite 102 Princeton NJ 08540 (609) 375-2227 false false false false Common Stock, $0.0001 Par Value SONN NASDAQ false XML 7 R1.htm IDEA: XBRL DOCUMENT v3.21.2
Cover
Dec. 17, 2021
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Dec. 17, 2021
Entity File Number 001-35570
Entity Registrant Name SONNET BIOTHERAPEUTICS HOLDINGS, INC.
Entity Central Index Key 0001106838
Entity Tax Identification Number 20-2932652
Entity Incorporation, State or Country Code DE
Entity Address, Address Line One 100 Overlook Center
Entity Address, Address Line Two Suite 102
Entity Address, City or Town Princeton
Entity Address, State or Province NJ
Entity Address, Postal Zip Code 08540
City Area Code (609)
Local Phone Number 375-2227
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock, $0.0001 Par Value
Trading Symbol SONN
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
EXCEL 8 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 9 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 10 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 11 FilingSummary.xml IDEA: XBRL DOCUMENT 3.21.2 html 1 96 1 false 0 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://sonnetbio.com/role/Cover Cover Cover 1 false false All Reports Book All Reports form8-k.htm ex99-1.htm sonn-20211217.xsd sonn-20211217_lab.xml sonn-20211217_pre.xml http://xbrl.sec.gov/dei/2021 true false JSON 13 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "form8-k.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "inline": { "local": [ "form8-k.htm" ] }, "labelLink": { "local": [ "sonn-20211217_lab.xml" ] }, "presentationLink": { "local": [ "sonn-20211217_pre.xml" ] }, "schema": { "local": [ "sonn-20211217.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "https://xbrl.sec.gov/dei/2021/dei-2021.xsd", "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd", "https://xbrl.sec.gov/country/2021/country-2021.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd" ] } }, "elementCount": 59, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2021": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 96, "memberCustom": 0, "memberStandard": 0, "nsprefix": "SONN", "nsuri": "http://sonnetbio.com/20211217", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "b", "span", "p", "body", "html" ], "baseRef": "form8-k.htm", "contextRef": "From2021-12-17to2021-12-17", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "00000001 - Document - Cover", "role": "http://sonnetbio.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "b", "span", "p", "body", "html" ], "baseRef": "form8-k.htm", "contextRef": "From2021-12-17to2021-12-17", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of changes contained within amended document.", "label": "Amendment Description" } } }, "localname": "AmendmentDescription", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://sonnetbio.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://sonnetbio.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AnnualInformationForm": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.", "label": "Annual Information Form" } } }, "localname": "AnnualInformationForm", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://sonnetbio.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AuditedAnnualFinancialStatements": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.", "label": "Audited Annual Financial Statements" } } }, "localname": "AuditedAnnualFinancialStatements", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://sonnetbio.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://sonnetbio.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CountryRegion": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Region code of country", "label": "Country Region" } } }, "localname": "CountryRegion", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://sonnetbio.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2021", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://sonnetbio.com/role/Cover" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAccountingStandard": { "auth_ref": [ "r11" ], "lang": { "en-us": { "role": { "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.", "label": "Document Accounting Standard" } } }, "localname": "DocumentAccountingStandard", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://sonnetbio.com/role/Cover" ], "xbrltype": "accountingStandardItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r9", "r11", "r12" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://sonnetbio.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://sonnetbio.com/role/Cover" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://sonnetbio.com/role/Cover" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://sonnetbio.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentPeriodStartDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.", "label": "Document Period Start Date" } } }, "localname": "DocumentPeriodStartDate", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://sonnetbio.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r10" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://sonnetbio.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentRegistrationStatement": { "auth_ref": [ "r18" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a registration statement.", "label": "Document Registration Statement" } } }, "localname": "DocumentRegistrationStatement", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://sonnetbio.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentShellCompanyEventDate": { "auth_ref": [ "r11" ], "lang": { "en-us": { "role": { "documentation": "Date of event requiring a shell company report.", "label": "Document Shell Company Event Date" } } }, "localname": "DocumentShellCompanyEventDate", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://sonnetbio.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentShellCompanyReport": { "auth_ref": [ "r11" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.", "label": "Document Shell Company Report" } } }, "localname": "DocumentShellCompanyReport", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://sonnetbio.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://sonnetbio.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://sonnetbio.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Documents incorporated by reference.", "label": "Documents Incorporated by Reference [Text Block]" } } }, "localname": "DocumentsIncorporatedByReferenceTextBlock", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://sonnetbio.com/role/Cover" ], "xbrltype": "textBlockItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://sonnetbio.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://sonnetbio.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine3": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 3 such as an Office Park", "label": "Entity Address, Address Line Three" } } }, "localname": "EntityAddressAddressLine3", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://sonnetbio.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://sonnetbio.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://sonnetbio.com/role/Cover" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://sonnetbio.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://sonnetbio.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.", "label": "Entity Bankruptcy Proceedings, Reporting Current" } } }, "localname": "EntityBankruptcyProceedingsReportingCurrent", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://sonnetbio.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://sonnetbio.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://sonnetbio.com/role/Cover" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://sonnetbio.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://sonnetbio.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r17" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Elected Not To Use the Extended Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://sonnetbio.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://sonnetbio.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://sonnetbio.com/role/Cover" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://sonnetbio.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r15" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://sonnetbio.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityPrimarySicNumber": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.", "label": "Entity Primary SIC Number" } } }, "localname": "EntityPrimarySicNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://sonnetbio.com/role/Cover" ], "xbrltype": "sicNumberItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://sonnetbio.com/role/Cover" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://sonnetbio.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://sonnetbio.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://sonnetbio.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://sonnetbio.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://sonnetbio.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://sonnetbio.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_Extension": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Extension number for local phone number.", "label": "Extension" } } }, "localname": "Extension", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://sonnetbio.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://sonnetbio.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_NoTradingSymbolFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a security having no trading symbol.", "label": "No Trading Symbol Flag" } } }, "localname": "NoTradingSymbolFlag", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://sonnetbio.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_OtherReportingStandardItemNumber": { "auth_ref": [ "r11" ], "lang": { "en-us": { "role": { "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.", "label": "Other Reporting Standard Item Number" } } }, "localname": "OtherReportingStandardItemNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://sonnetbio.com/role/Cover" ], "xbrltype": "otherReportingStandardItemNumberItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://sonnetbio.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://sonnetbio.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://sonnetbio.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_Security12gTitle": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(g) registered security.", "label": "Title of 12(g) Security" } } }, "localname": "Security12gTitle", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://sonnetbio.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://sonnetbio.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SecurityReportingObligation": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.", "label": "Security Reporting Obligation" } } }, "localname": "SecurityReportingObligation", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://sonnetbio.com/role/Cover" ], "xbrltype": "securityReportingObligationItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r8" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://sonnetbio.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://sonnetbio.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r16" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://sonnetbio.com/role/Cover" ], "xbrltype": "booleanItemType" } }, "unitCount": 3 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-23" }, "r10": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a" }, "r11": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f" }, "r12": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f" }, "r13": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1" }, "r14": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r15": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r16": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" }, "r17": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2" }, "r18": { "Name": "Securities Act", "Number": "Section", "Publisher": "SEC", "Section": "12" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "g" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12, 13, 15d" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r6": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r7": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "15", "Subsection": "d" }, "r8": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r9": { "Name": "Form 10-K", "Number": "249", "Publisher": "SEC", "Section": "310" } }, "version": "2.1" } ZIP 14 0001493152-21-031802-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001493152-21-031802-xbrl.zip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ϙ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end